Navigation Links
Beckman Coulter Announces Licensing Option Agreements for Cancer Genes with Johns Hopkins University
Date:10/30/2007

Contracts Establish Exclusive Access to Diagnostic Application of Research

Discoveries

FULLERTON, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC) announced today that it has signed two agreements with Johns Hopkins University giving the company exclusive options to license cancer genomics intellectual property. The first agreement covers 200 genes linked to breast and colon cancer, discovered in a landmark study published last year by researchers at Johns Hopkins Kimmel Cancer Center. Beckman Coulter Agencourt subsidiary's Genomic Services performed the sequencing for this study, which was co-authored by James Hartigan, an Agencourt project manager. The second agreement covers sequencing services and options to license genomic intellectual property from current studies on six additional cancers.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO)

"These unprecedented agreements put Beckman Coulter in a unique, leading- edge position in the molecular diagnostics field," commented Bruce Wallace, vice president of Beckman Coulter's Molecular Diagnostics Business Center. "Beckman Coulter will have the exclusive option to license any of the genetic mutations discovered in these studies that have diagnostic potential. Given the leadership role Johns Hopkins is playing in cancer genetics, our relationship with them will help propel us to the forefront of this rapidly developing field."

With these new agreements, Beckman Coulter will have first access to Johns Hopkins cancer study data. The company's molecular diagnostics assay group is already evaluating the breast and colon cancer genes. "The success of our strategic plan is dependent in part on our development of a robust molecular diagnostics business," Wallace continued. "We are already in the process of moving our research genomics technologies into platforms for diagnostic use. Building content, or approved tests for that platform, from research such as the John Hopkins cancer genomics studies, will enhance our success."

Agencourt Bioscience Corporation, a wholly owned subsidiary of Beckman Coulter, is a leading provider of nucleic acid purification products and genomic services for life science research. The company's products and services are based on the patented Agencourt SPRI(R) (Solid Phase Reversible Immobilization) paramagnetic bead-based technology.

Beckman Coulter, Inc., based in Fullerton, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits, service and operating-type lease payments, represents more than 75 percent of the company's 2006 annual revenue of $2.53 billion. For more information, visit http://www.beckmancoulter.com.

Contacts: Mary Luthy

Corporate Communications, Beckman Coulter

Phone: (714) 993-8770

E-mail: mluthy@beckman.com

Robert Raynor, Ph.D.

Investor Relations, Beckman Coulter

Phone: (714) 773-7620

E-mail: rraynor@beckman.com


'/>"/>
SOURCE Beckman Coulter, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com recently ... of Eyeglasses . , Millions of individuals in the United States and Canada ... become a way to both correct vision and make a fashion statement. Even celebrities ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology: